Medical therapy for ulcerative colitis 2004

Gastroenterology

Volumn 126, Issue 6, 2004, Pages 1582-1592

  Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ALPHA2A INTERFERON; AMINOSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; BASILIXIMAB; BETA1A INTERFERON; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; GROWTH FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; MLN 02; NATALIZUMAB; OLSALAZINE; PEGINTERFERON; PREDNISOLONE; PROBIOTIC AGENT; PURINE ANTAGONIST; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

CHEMOPROPHYLAXIS; COLON RESECTION; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HYPERSENSITIVITY; ILEITIS; IMMUNOMODULATION; LONG TERM CARE; LYMPHOCYTOPENIA; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; ULCERATIVE COLITIS; VIRUS REACTIVATION;

EID: 2442526434     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.02.071     Document Type: Article

References (132)

1. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003:CD000543.
2. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002:CD000544.
3. Ragunath K, Williams JG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther 2001;15:1549-1554.
4. Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002;16:61-68.
5. Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002;16:69-77.
6. Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am J Gastroenterol 2002;97:1283-1285.
7. Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosallcylates for ulcerative colitis. Am J Gastroenterol 2003;98:215-216.
8. Johnson LK, Pruitt RE, Green JR. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercom and letter to the editor by Dr. Hanauer. Am J Gastroenterol 2003;98:216-219.
9. Sandbom WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. (review) Am J Gastroenterol 2002;97:2939-2941.
10. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003;3:210-218.
11. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15-22.
12. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-1407.
13. Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-3086.
14. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42.
15. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188-1197.
16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629.
17. Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991;115:350-355.
18. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988;95:975-981.
19. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-1276.
20. Kruls W, Bar-Meir S, Feher J, Mickisch U, Mlitz H, Faszcyk M, Chowers Y, Lengyele G, Kovacs A, Lakotos L, Stolte M, Vieth M, Greinwald R. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36-43.
21. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-211.
22. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:204-211.
23. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-2933.
24. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39-43.
25. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:191-198.
26. Robinson A, Thompson DG, Wilkin D, Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001;358:976-981.
27. Refojo D, Liberman A, Holsboer F, Arzt E. Transcription factor-mediated molecular mechanisms involved in the functional cross-talk between cytokines and glucocorticoids. Immunol Cell Biol 2001;79:385-394.
28. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142.
29. Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000;47:71-82.
30. Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease-do we have reliable markers? Inflamm Bowel Dis 2000;6:123-131.
31. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-835.
32. Schottelius A, Wedel S, Weltrich R, Rohde W, Buttgereit F, Schreiber S, Lochs H. Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol 2000;95:1994-1999.
33. Flood L, Lofberg R, Stiema P, Wikstrom AC. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis 2001;7:202-209.
34. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinfiammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci U S A 2001;98:6865-6870.
35. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-866.
36. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
37. Kombluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 1995;20:280-284.
38. Sood A, Midha V, Sood N, Awasthi G. A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis. J Clin Gastroenterol 2002;35:328-331.
39. Rembacken BJ, Snelling AM, Hawkey PM, Chambers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazlne for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639.
40. Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:591-603.
41. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, Persson T, Salde L. The Mesalamine Study Group. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713-1718.
42. Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A, Castiglione GN, Varoli G, Campieri M. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109-1116.
43. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628-1636.
44. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16-19.
45. Lichtiger S, Present DH, Kornbluth A, Gelemt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
46. Sandborn WJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg 2001;64:201-204.
47. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-1329.
48. Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:303-308.
49. Van Assche G, D'Haens G, Noman M, Vermeire S, Hlele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-1031.
50. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-2008.
51. Actis GC, Ottobrelli A, Pera A, Barletti C, Ponti V, Pinna-Pintor M, Verme G. Continuously infused cyclosporlne at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993;17:10-13.
52. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998;4:276-279.
53. Navazo L, Salata H, Morales S, Dorta MC, Perez F, de las Cases D, Avlles J. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and Indeterminate colitis. Scand J Gastroenterol 2001;36:610-614.
54. Bousvaros A, Kirschner BS, Werlln SL, Parker-Hartigan L, Daum F, Freeman KB, Ballnt JP, Day AS, Griffiths AM, Zurakowski D, Ferry GD, Leichtner AM. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794-799.
55. Matsuhashi N, Nakajima A, Watanabe K, Komeno Y, Suzuki A, Ohnishi S, Omata M, Kondo K, Usul Y, Iwadare JI, Wantanabe T, Nagawa H, Muto T. Tacrollmus in corticosteroid-resistant ulcerative colitis. J Gastroenterol 2000;35:635-640.
56. Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995;38:1241-1245.
57. Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-1440.
58. Su CG, Stein RB, Lewis JD, Lichtenstein GR. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? Dig Liver Dis 2000;32:518-531.
59. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-489.
60. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4:627-630.
61. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-99.
62. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-1292.
63. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-22.
64. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001;13:1297-1301.
65. Lobo AJ, Foster PN, Burke DA, Johnston D, Axon AT. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-377.
66. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopu-rine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-722.
67. George J, Present DH, Pou R, Bodian C, Runin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-1714.
68. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227-1233.
69. Actis GC, Bresso F, Astegiano M, Demarchi B, Sapone N, Boscaglia C, Rizzetto M. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001;15:1307-1311.
70. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94:1587-1592.
71. Falasco G, Zinicola R, Forbes A. Review article: immuno-suppressants in distal ulcerative colitis. Aliment Pharmacol Ther 2002;16:181-187.
72. Mahadevan U, Loftus EV Jr, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311-316.
73. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-646.
74. Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001;13:1073-1076.
75. Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:506-511.
76. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-1145.
77. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-88.
78. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-2381.
79. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7(Suppl 1):S30-S33.
80. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001;113:930-933.
81. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Dapemo M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34:626-630.
82. Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-2584.
83. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34:631-634.
84. Gornet JM, Couve S, Hassani Z, Delchier JC, Marteau P, Cosnes J, Bouhnik Y, Dupas JL, Modigliani R, Taillard F, Lemann M. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003;18:175-181.
85. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Amott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
86. Evans RC, Clarke L, Heath P, Stephens S, Morris Al, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-1035.
87. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-α and IFN-γ m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995;46:111-123.
88. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-181.
89. Nielsen OH, Gionchetti P, Ainsworth M, Vainer B, Campieri M, Borregaard N, Kjeldsen L. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94:2923-2928.
90. Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:616-622.
91. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997;40:628-633.
92. Iyer S, Kontoyiannis D, Chevrier D, Woo J, Mori N, Comejo M, Kollias G, Buelow R. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000;275:17051-17057.
93. Iyer S, Lahana R, Buelow R. Rational design and development of RDP58. Curr Pharm Des 2002;8:2217-2229.
94. Travis S, Yap L, Hawkey CJ. Novel and effective therapy for ulcerative colitisresults of parallel, prospective, placebo-controlled trials (abstr). Am J Gastroenterol 2003;98:S239.
95. Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705.
96. Feagan B, Greenberg GR, Wild G. A randomized controlled trial of a humanized alpha4beta7 antibody in ulcerative colitis. (abstr) Am J Gastroenterol 2003;98:S248-S249.
97. Miner P, Bane B, Bradley J. ICAM-1 antisense inhibition by enema improves pouchitis and suggests long-term mucosal healing in patients with chronic unremitting disease (abstr). Am J Gastroenterol 2003;98:S246-S247.
98. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-376.
99. Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75.
100. Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C, Vasquez M, Tso JY. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 1999;68:563-571.
101. Plevy SE, Salzberg BA, Regueiro M. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: preliminary results of a phase I study (abstr). Gastroenterology 2003;124:A7
102. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, Anasetti C. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712-2719.
103. Cottone M, Magliocco A, Trallori G, Brignola C, Vandelli C, Ardizzone S, Meucci G, Zannoni F, Di Maio G, Astegiano M. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995;27:3-4.
104. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:597-602.
105. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, Munkholm P. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-1815.
106. Tilg H, Vogelsang H, Ludwiczek O. A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis (abstr). Gastroenterology 2003;124:A62.
107. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002;16:1233-1239.
108. Musch E, Raedler A, Andus T. A phase II placebo-controlled, randomized, multicenter study to evaluate efficiency and safety of interferon beta-1a in patients with ulcerative colitis. (abstr) Gastroenterology 2002;122:A431.
109. Nikolaus S, Rutgeerts P. Fedorak R, Steinhart AH, Wild GE, Theuer D, Mohrle J, Schreiber S. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52:1286-1290.
110. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999;5:44-60.
111. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loffus EV Jr, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003;17:1355-1364.
112. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-357.
113. Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 2003;18:392-400.
114. Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):15-21.
115. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-2788.
116. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10-14.
117. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentriall TA. Ursodlol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
118. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-893.
119. Bemdtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis - a prospective study. Colorectal Dis 2003;5:173-179.
120. Delaney CP, Fazio VW, Remzi FH, Hammel J, Church JM, Hull TL, Senagore AJ, Strong SA, Lavery IC. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg 2003;238:221-228.
121. Michelassi F, Lee J, Rubin M, Fichera A, Kasza K, Karrison T, Hurst RD. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg 2003;238:433-441; discussion 442-445.
122. Stein RB, Lichtenstein GR. Complications after ileal pouch-anal anastomosis. Semin Gastrointest Dis 2000;11:2-9.
123. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003;238:229-234.
124. Ording O, Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-19.
125. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003;124:1636-1650.
126. Sandbom W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev 2000:2.
127. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-917.
128. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Migioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209.
129. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacterio-therapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.
130. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Glonchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-114.
131. Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, Huemos S, Kogan Z, Cabanne A, Graziano A, Peredo H, Doidan I, Gonzalez O, Sugai E, Lumi M, Bai JC. Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002;16:27-34.
132. Colombel JF, Ricart E, Loftus EV Jr, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandbom WJ. Management. of Crohn's disease of the Ileoanal pouch with infliximab. Am J Gastroenterol 2003;9 8:2239-2244.